907 related articles for article (PubMed ID: 28535410)
1. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
[TBL] [Abstract][Full Text] [Related]
2. The practical impact of altered dosing on perampanel plasma concentrations: pharmacokinetic modeling from clinical studies.
Gidal BE; Majid O; Ferry J; Hussein Z; Yang H; Zhu J; Fain R; Laurenza A
Epilepsy Behav; 2014 Jun; 35():6-12. PubMed ID: 24785428
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects.
Boinpally R; Gad N; Gupta S; Periclou A
Clin Ther; 2014 Nov; 36(11):1638-49. PubMed ID: 25236915
[TBL] [Abstract][Full Text] [Related]
4. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
Gidal BE; Ferry J; Majid O; Hussein Z
Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
[TBL] [Abstract][Full Text] [Related]
5. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
Noh YH; Lim HS; Jin SJ; Kim MJ; Kim YH; Sung HR; Choi HY; Bae KS
Clin Ther; 2012 May; 34(5):1182-94. PubMed ID: 22534255
[TBL] [Abstract][Full Text] [Related]
6. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
7. Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study.
Venkatakrishnan K; Rader M; Ramanathan RK; Ramalingam S; Chen E; Riordan W; Trepicchio W; Cooper M; Karol M; von Moltke L; Neuwirth R; Egorin M; Chatta G
Clin Ther; 2009; 31 Pt 2():2444-58. PubMed ID: 20110052
[TBL] [Abstract][Full Text] [Related]
8. An adaptive design to investigate the effect of ketoconazole on pharmacokinetics of GSK239512 in healthy male volunteers.
Xu J; Hilpert J; Wu K; van Hecke B; Collins G; Patel A; Mohindra R; Davies MJ; Xu Y; Thompson P
J Clin Pharmacol; 2015 May; 55(5):505-11. PubMed ID: 25470032
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of Perampanel in Healthy Korean, White, and Japanese Adult Subjects.
Tabuchi H; Shiba S; Yasuda S; Ohnishi A; Shin JG
Clin Pharmacol Drug Dev; 2018 Aug; 7(6):613-620. PubMed ID: 29870595
[TBL] [Abstract][Full Text] [Related]
11. In Silico Predictions and In Vivo Results of Drug-Drug Interactions by Ketoconazole and Verapamil on AZD1305, a Combined Ion Channel Blocker and a Sensitive CYP3A4 Substrate.
Johansson S; Löfberg B; Aunes M; Lunde H; Frison L; Edvardsson N; Cullberg M
Clin Pharmacol Drug Dev; 2016 Sep; 5(5):364-73. PubMed ID: 27627192
[TBL] [Abstract][Full Text] [Related]
12. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
[TBL] [Abstract][Full Text] [Related]
13. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects.
Abbas R; Hug BA; Leister C; Burns J; Sonnichsen D
J Clin Pharmacol; 2011 Dec; 51(12):1721-7. PubMed ID: 21148045
[TBL] [Abstract][Full Text] [Related]
14. Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions.
Boetsch C; Parrott N; Fowler S; Poirier A; Hainzl D; Banken L; Martin-Facklam M; Hofmann C
Clin Pharmacokinet; 2016 Feb; 55(2):237-47. PubMed ID: 26341813
[TBL] [Abstract][Full Text] [Related]
15. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
Frost CE; Byon W; Song Y; Wang J; Schuster AE; Boyd RA; Zhang D; Yu Z; Dias C; Shenker A; LaCreta F
Br J Clin Pharmacol; 2015 May; 79(5):838-46. PubMed ID: 25377242
[TBL] [Abstract][Full Text] [Related]
16. Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.
Li J; Kankam M; Trone D; Gammon G
Br J Clin Pharmacol; 2019 Sep; 85(9):2108-2117. PubMed ID: 31173645
[TBL] [Abstract][Full Text] [Related]
17. The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects.
Xu H; O'Gorman M; Tan W; Brega N; Bello A
Eur J Clin Pharmacol; 2015 Dec; 71(12):1441-9. PubMed ID: 26381275
[TBL] [Abstract][Full Text] [Related]
18. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
19. Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
Wrishko RE; McCrea JB; Yee KL; Liu W; Panebianco D; Mangin E; Chakravarthy M; Martinez-Cantarin MP; Kraft WK
Clin Drug Investig; 2019 May; 39(5):441-451. PubMed ID: 30810914
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers.
Shaik MN; LaBadie RR; Rudin D; Levin WJ
Cancer Chemother Pharmacol; 2014 Aug; 74(2):411-8. PubMed ID: 24944041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]